Read on Twitter
We have seen multiple new, effective, treatments approved for HCC!
That called for updated SYSTEMIC THERAPY guidelines!
Great work by the @ASCO Guidelines team (Erin Kennedy) and the Co-Chairs!
#ascoguidelines
#hbpsm
https://pubmed.ncbi.nlm.nih.gov/33197225/
That called for updated SYSTEMIC THERAPY guidelines!
Great work by the @ASCO Guidelines team (Erin Kennedy) and the Co-Chairs!
#ascoguidelines
#hbpsm
https://pubmed.ncbi.nlm.nih.gov/33197225/
Systemic therapy for HCC:
1st line therapy:
- Atezo/Bev (Preferred)
- TKI (Sorafenib/Lenvatinib)
#ascoguidelines
#hbpsm
1st line therapy:
- Atezo/Bev (Preferred)
- TKI (Sorafenib/Lenvatinib)
#ascoguidelines
#hbpsm
Systemic therapy for HCC-- 2nd Line Therapy:
If Atezo/Bev 1st line -> sorafenib/lenvatinib
Can consider cabozantinib/rego too
#ascoguidelines
#hbpsm
If Atezo/Bev 1st line -> sorafenib/lenvatinib
Can consider cabozantinib/rego too
#ascoguidelines
#hbpsm
HCC systemic therapy :
Areas of uncertainty:
- Sequencing of therapy
- Lack of adequately powered
studies to identify subgroups
Unmet need:
- Child-Pugh B patients
-Molecularly targeted treatments
- Third line?
#ascoguidelines
#hbpsm
Areas of uncertainty:
- Sequencing of therapy
- Lack of adequately powered
studies to identify subgroups
Unmet need:
- Child-Pugh B patients
-Molecularly targeted treatments
- Third line?
#ascoguidelines
#hbpsm
HCC systemic therapy has come a long way.
Challenges:
- Health disparities persist
- Treatments can be toxic
- Cost of care is OUTRAGEOUS
- Trial participants don't reflect the 'typical' patient w HCC
#ascoguidelines
#hbpsm
Challenges:
- Health disparities persist
- Treatments can be toxic
- Cost of care is OUTRAGEOUS
- Trial participants don't reflect the 'typical' patient w HCC
#ascoguidelines
#hbpsm
Future studies are evaluating combinations of IO/IO and IO/TKI.
Hope to see more effective treatments in coming years!
Hope to see more effective treatments in coming years!
